TELA Bio, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
TELA Bio CEO Heather Getz bought 12,500 shares at $0.6649 each, totaling $8,311. She now holds 532,500 shares. TELA's stock has gained 15.5% in a week but is down 54% year-over-year. InvestingPro values the stock at $1.06. Q2 earnings missed expectations, with a loss of $0.20 per share and revenue of $19.3M. The company withdrew 2026 revenue guidance but noted gross margin improvements and growth in some segments.
TELA Bio's COO and CFO Roberto Cuca resigned. CEO Heather Getz announced a restructuring to cut annual operating expenses by $17M, reducing headcount by 20% and extending cash runway into 2028. A one-time $1.5M restructuring charge is expected in Q3. Details will be discussed in an earnings call in November.
Tela Bio, a medical-tech company, plans to cut 20% of its workforce, reducing headcount from 201 to 160, aiming to cut $17M in annual operating expenses. The company reported $80M in revenue last year but operates at a loss. CEO Heather Getz expects the layoffs to cost $1.5M in severance and extend cash runway into 2028.
Over the past 7 days, alphai's AI scored 5 news stories mentioning TELA (TELA Bio, Inc.). Coverage has skewed bearish: 0 bullish, 3 neutral, and 2 bearish.
Recent TELA coverage spans earnings, corporate actions and financial news.
In the last 30 days, TELA insiders filed 2 SEC Form 4 transactions — 2 purchases ($19K) and no sales. The most active reporter was Getz Heather C, Chief Executive Officer, with 2 filings.
Insider buying signals confidence, but earnings miss and guidance withdrawal suggest near‑term pressure.
Potential short-term stock pressure from leadership change and upcoming restructuring costs.
Layoffs signal cost discipline but highlight ongoing losses; short-term stock pressure likely.
Cost cuts aim to extend cash runway to 2028, potentially supporting the stock price.
Executive departure and sizable cost cuts may pressure the stock short‑term but could improve margins long‑term.
alphai scores every news story that mentions TELA with an AI model for sentiment and relevance, and aggregates insider trades from TELA Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TELA Bio CEO Heather Getz bought 12,500 shares at $0.6649 each, totaling $8,311. She now holds 532,500 shares. TELA's stock has gained 15.5% in a week but is down 54% year-over-year. InvestingPro values the stock at $1.06. Q2 earnings missed expectations, with a loss of $0.20 per share and revenue of $19.3M. The company withdrew 2026 revenue guidance but noted gross margin improvements and growth in some segments.
2 min readTELA Bio's COO and CFO Roberto Cuca resigned. CEO Heather Getz announced a restructuring to cut annual operating expenses by $17M, reducing headcount by 20% and extending cash runway into 2028. A one-time $1.5M restructuring charge is expected in Q3. Details will be discussed in an earnings call in November.
2 min readTela Bio, a medical-tech company, plans to cut 20% of its workforce, reducing headcount from 201 to 160, aiming to cut $17M in annual operating expenses. The company reported $80M in revenue last year but operates at a loss. CEO Heather Getz expects the layoffs to cost $1.5M in severance and extend cash runway into 2028.
2 min readTELA Bio (NASDAQ:TELA) announced a 20% workforce reduction to cut annual costs by $17M. COO/CFO Roberto Cuca will step down. The company expects a $1.5M restructuring charge in Q3 2026. The move aims to extend cash runway into 2028. Details will be shared during the Q3 2026 earnings call.
2 min readTELA Bio, Inc. (TELA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program MALVERN, PA, August 31, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a c
1 min readGetz Heather C (Chief Executive Officer) purchased 12,500 shares of TELA Bio, Inc. (TELA) at $0.66 on 2026-08-17.
1 min readTELA Bio reported Q2 2026 revenue of $19.3M, down 4% YoY, driven by declines in OviTex PRS unit volumes and price-mix headwinds. International revenue grew 26% YoY, while gross margin improved to 72%. Net loss was $11.3M, and cash reserves decreased to $30.4M. Management cited competitive pressures and slower sales rep productivity as challenges, while highlighting market share gains in hernia products and plans to reduce costs.
3 min readGetz Heather C (Chief Executive Officer) purchased 15,000 shares of TELA Bio, Inc. (TELA) at $0.70 on 2026-08-14.
1 min readTELA Bio, Inc. (NASDAQ: TELA) appointed Heather Getz as CEO and director effective Aug. 9, replacing co-founder Antony Koblish as the company targets commercial growth. Getz previously served as CFO and COO at Butterfly Network (NYSE: BFLY). TELA Bio said Getz will focus on commercial execution and customer relationships.
3 min readTELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TELA Bio Reports Second Quarter 2026 Financial Results MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results fo
4 min read
